BCM
ATRA icon

Bayesian Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Bayesian Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,734
Closed -$164K – 779
2022
Q3 		$164K Buy
+1,734
New +$195K 0.03% 547

Other funds holding ATRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bayesian Capital Management's ATRA Position: Q4 2022 in Review

Bayesian Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 1,734 shares — an estimated $164K sold.

Bayesian Capital Management first reported a position in ATRA in Q3 2022 and held it in 1 quarter. The position peaked at $164K in Q3 2022. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

  • Bayesian Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 1,734 Atara Biotherapeutics shares in Q4 2022, an estimated $164K.
  • Bayesian Capital Management first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Atara Biotherapeutics position peaked at $164K in Q3 2022.
  • 139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Bayesian Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.